[Trisomy of chromosome 8 in Ph-negative cells of the bone marrow in patients with chronic myeloid leukemia treated with inhibitors of BCR-ABL tyrosine kinases].
OBJECTIVE
To analyse clinical implications of chromosome 8 trisomy in Ph-negative cells of the bone marrow in patients with chronic myeloid leukemia (CML) treated with inhibitors of tyrosinkinases (ITK).


METHODS
A total of 386 patients with CML (chronic phase--288, acceleration phase--77) received imatinib (400-800 mg/day). Because of resistance and/or intolerance some patients were switched to ITK II (nilotinib, dasatinib, bozutinib). This study included 8 CML patients (7 in a chronic phase, 1 in acceleration phase) treated with BCR-ABL ITK inhibitors of the first (imatinib) and the second line (ITK-II). The standard cytogenetic examination, on demand--investigation of the interphase nuclei with FISH, in some cases morphological, cytochemical and histological examinations of the bone marrow were made.


RESULTS
The existence of a Ph-negative clone with trisomy of chromosome 8 had no negative effect on the course of the disease. The patients showed a stable hematological and cytogenetic response and no need in changing treatment policy. In long-term follow-up Ph-negative clone with trisomy of the chromosome 8 persisted without a clear trend to rise in most patients.


CONCLUSIONS
Detection of a Ph-negative clone with chromosome 8 trisomy at early stages suggests parallel existence of Ph-positive and Ph-negative clones. None of the patients had myelodisplasia.
Turkina
A G
AG
Domracheva
E V
EV
Vorontsova
A V
AV
Aseeva
E A
EA
Vinogradova
O Iu
OIu
Stakhina
O V
OV
Gusarova
G A
GA
Diagileva
O A
OA
Semenova
E A
EA
Vakhrusheva
M V
MV
Kolosheĭnova
T I
TI
Abakumov
E M
EM
Chelysheva
E Iu
EIu
Goriacheva
S R
SR
Ivanova
T V
TV
Zakharova
E S
ES
Kolosova
L Iu
LIu
Zakharova
A V
AV
Naumova
I N
IN
Diachenko
L V
LV
Kulikov
S M
SM
Kovaleva
L G
LG
Khoroshko
N D
ND
D000328:Adult; D001549:Benzamides; D001854:Bone Marrow Cells / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D002898:Chromosomes, Human, Pair 8 / Q000235:genetics*; D004334:Drug Administration Schedule; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors*; D006801:Humans; D000068877:Imatinib Mesylate; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D008297:Male; D008875:Middle Aged; D010677:Philadelphia Chromosome / Q000187:drug effects*; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D014314:Trisomy
D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; C498826:nilotinib